Biocept Says Receives South Korean Patent For Primer-Switch Platform Used To Identify Rare Genetic Mutations, Including Cancer Biomarkers
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays and services, has been awarded a South Korean Patent for its Primer-Switch technology, which detects rare mutations in circulating tumor DNA